Screening for dipeptidyl peptidase Ⅳ inhibitors research
Dipeptidyl peptidase Ⅳ （dipeptidyl peptidase IV, DPP-IV; EC3.4.14.5/CD26） is an important target for the treatment of diabetes which is one kind of proline 01igopeptide of serine aminopeptidase. It has been showed that glucagon-like peptide-1 have significant hypoglycemic effects in vitro and in vivo. However, GLP-1 action has a very shot half life of about 2 min due to its degradation by DPP-Ⅳ, which limited its clinical application. DPP-Ⅳ inhibitors have been proved to prevent GLP-1 degradation and thus effectively
NETL
NSTL
万方数据
维普
